SELLAS Life Sciences is advancing its acute myeloid leukemia (AML) treatment with its lead drug galinpepimut-S (GPS) approaching pivotal Phase 3 trial results in the REGAL study. The company also progresses another candidate, SLS009, targeting high-risk AML. With $135.8 million in cash, SELLAS is well-funded for upcoming critical data releases and potential commercialization. Despite a high valuation, the near-term catalysts and clinical potential make it an attractive growth biotech to watch.
The U.S. Department of Labor's proposed rule on fiduciary duties for 401(k) investment selections has ignited a heated debate over allowing alternative assets like Bitcoin and private funds in retirement plans. Lawmakers including Senators Sanders an...
Kalshi has secured FIFA World Cup branding exposure through a partnership with ADI Predictstreet, FIFA’s official prediction market partner for the 2026 tournament. This deal enhances Kalshi’s sports presence as its daily trading volume surpasses $1 ...
Aave Labs CEO Stani Kulechov dismissed reports of Kraken acquiring a 15% stake in Aave Group, clarifying that Aave would never sell at a steep discount. Despite uncertainty over the deal, AAVE's price surged 12%, extending a 50% rally in June, driven...
A new decentralized finance (DeFi) application on Solana has introduced cross-chain swap functionality, allowing users to move assets seamlessly between Solana and other blockchain networks. This feature simplifies the process by reducing the need fo...
Tony Huang of Advent Capital Management explains how the Advent Convertible and Income Fund (AVK) uses a mix of convertible securities and high-yield bonds to target both income and total return. The fund's strategy is influenced by factors like corp...
